Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 176 to 200 of 332

Guidance and quality standards awaiting development
Title	Type
Mepolizumab for reducing eosinophilic exacerbations of chronic obstructive pulmonary disease ID1237	Technology appraisal guidance
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)	Health technology evaluation
Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment [ID6513]	Technology appraisal guidance
Middle meningeal artery embolisation for chronic subdural haematomas	Interventional procedures guidance
MIM8 for preventing bleeding episodes in haemophilia A in people 1 year and over [ID6400]	Technology appraisal guidance
Mirabegron for treating neurogenic detrusor overactivity in people aged 3 to 17 [TSID10730]	Technology appraisal guidance
Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [ID12203]	Technology appraisal guidance
Navepegritide for treating achondroplasia in people 2 to 15 years [ID6538]	Technology appraisal guidance
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]	Technology appraisal guidance
Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over [TSID11777]	Technology appraisal guidance
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]	Technology appraisal guidance
Nicardipine (Nicaplant) for aneurysmal subarachnoid haemorrhage patients undergoing aneurysm clipping [TSID10593]	Technology appraisal guidance
Nipocalimab for treating generalised myasthenia gravis [ID6562]	Technology appraisal guidance
Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer [ID6595]	Technology appraisal guidance
Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]	Technology appraisal guidance
Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma [TSID9659]	Technology appraisal guidance
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]	Technology appraisal guidance
Norucholic acid for treating primary sclerosing cholangitis [ID6583]	Technology appraisal guidance
Obicetrapib or obicetrapib–ezetimibe for treating primary heterozygous hypercholesterolaemia or mixed dyslipidaemia [ID6519]	Technology appraisal guidance
Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy [TSID11996]	Technology appraisal guidance
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912]	Technology appraisal guidance
Onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [TSID12168]	Technology appraisal guidance
Ondansetron for treating alcohol-use disorder [ID6341]	Technology appraisal guidance
Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease TS ID 11941	Technology appraisal guidance
Orforglipron for managing overweight and obesity [ID6516]	Technology appraisal guidance

Results per page

10
25
50
All